Journal
THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE
Volume 10, Issue 6, Pages 534-548Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/1753465816667659
Keywords
anti-interleukin-5 monoclonal antibodies; benralizumab; biomarkers; cytokines; eosinophils; interleukin 5; severe asthma
Categories
Ask authors/readers for more resources
Despite several therapeutic choices, 10-20% of patients with severe uncontrolled asthma do not respond to maximal best standard treatments, leading to a healthcare expenditure of up to 80% of overall costs for asthma. Today, there are new important therapeutic strategies, both pharmacological and interventional, that can result in improvement of severe asthma management, such as omalizumab, bronchial thermoplasty and other biological drugs, for example, mepolizumab, reslizumab and benralizumab. The availability of these new treatments and the increasing knowledge of the different asthmatic phenotypes and endotypes makes correct patient selection increasingly complex and important. In this article, we discuss the features of benralizumab compared with other anti-interleukin-5 biologics and omalizumab, the identification of appropriate patients, the safety profile and future developments.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available